| Description | Human adipocytes (HPAd) provide an ideal cell model and facilitate life science research and drug discovery for obesity, diabetes and cardiovascular diseases. We extract HPAd from human subcutaneous and cardiac adipose tissue, and cryopreserve these fibroblast-like precursor cells at the end of the Human adipocytes (HPAd) provide an ideal cell model and facilitate life science research and drug discovery for obesity, diabetes and cardiovascular diseases. We extract HPAd from human subcutaneous and cardiac adipose tissue, and cryopreserve these fibroblast-like precursor cells at the end of the primary culture. They can be transmitted for two passages before differentiating into human adipocytes (HAd). Complete differentiation can be easily achieved by using pre-adipocyte differentiation medium. It is expected that mature HAd should remain healthy 10 days after differentiation induction and should respond within at least 2 weeks after full differentiation. The fat mass can be controlled by inhibiting the differentiation of HPAd and increasing the lipolysis effect. HPAd can also be pre-screened to express adipocyte markers.... Read More | Bifidobacterium are Gram-positive, heterofermentative, anaerobic bacteria with a distinctive bifid; i.e. Y shape after which they are named. They wre originally isolated from the faeces of breast-fed infants, members of the genus Bifidobacterium are commonly found in the GI tract of mammals. In Bifidobacterium are Gram-positive, heterofermentative, anaerobic bacteria with a distinctive bifid; i.e. Y shape after which they are named. They wre originally isolated from the faeces of breast-fed infants, members of the genus Bifidobacterium are commonly found in the GI tract of mammals. In humans, Bifidobacterium resides within the GI tract, from birth to old age. Disturbances in the microbiota are linked to an ever-growing number of immune-linked disease states including IBD, atopic allergy, arthritis, and obesity. Therefore, there is a significant interest in treating these diseases through microbial or "probiotic" supplementation of patients, including Bifidobacterium. Data from mouse models and clinical trials indicate that Bifidobacterium may have beneficial effects for treating and preventing immune-linked diseases, including gut-associated and systemic conditions. Bifidobacterium have been commercially exploited as probiotic agents due to their associated health benefits and GRAS; Generally Recognised As Safe status.... Read More | This product GTVCR-WQ1664MR is an effective transcription system suitable for a variety of research, including the in vitro translation, self-amplifying mRNA studies and protein expression. The system was driven by the T7 promoter to efficiently generate mRNA with 120 nt poly(A) tail ecoding This product GTVCR-WQ1664MR is an effective transcription system suitable for a variety of research, including the in vitro translation, self-amplifying mRNA studies and protein expression. The system was driven by the T7 promoter to efficiently generate mRNA with 120 nt poly(A) tail ecoding antibody which targeting EPHA3. The vector contains the self-replicating Venezuelan equine encephalitis (VEE) virus RNA replicon, which resulting the mRNA expression at a high level.... Read More | This product is a 38.6 kDa Human GPR20 membrane protein expressed in HEK293. The protein is for research use only and is not approved for use in humans or in clinical diagnosis. | SARS-CoV-2 Inactivated Virus Particles is chemically modifie to be non-infectious intact viral particles. The inactivation was verified in a standard microbiological growth protocol. Based on our in-house RT-PCR assay to detect the N proteins, it indicates that our product includes 1,000,000 copies SARS-CoV-2 Inactivated Virus Particles is chemically modifie to be non-infectious intact viral particles. The inactivation was verified in a standard microbiological growth protocol. Based on our in-house RT-PCR assay to detect the N proteins, it indicates that our product includes 1,000,000 copies per mL.... Read More |